0001159036-26-000074.txt : 20260603 0001159036-26-000074.hdr.sgml : 20260603 20260603200658 ACCESSION NUMBER: 0001159036-26-000074 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20260601 FILED AS OF DATE: 20260603 DATE AS OF CHANGE: 20260603 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Torley Helen CENTRAL INDEX KEY: 0001528185 ORGANIZATION NAME: FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-32335 FILM NUMBER: 261062825 MAIL ADDRESS: STREET 1: 12390 EL CAMINO REAL CITY: SAN DIEGO STATE: CA ZIP: 92130 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: HALOZYME THERAPEUTICS, INC. CENTRAL INDEX KEY: 0001159036 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] ORGANIZATION NAME: 03 Life Sciences EIN: 880488686 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 12390 EL CAMINO REAL CITY: SAN DIEGO STATE: CA ZIP: 92130 BUSINESS PHONE: (858) 794-8889 MAIL ADDRESS: STREET 1: 12390 EL CAMINO REAL CITY: SAN DIEGO STATE: CA ZIP: 92130 FORMER COMPANY: FORMER CONFORMED NAME: HALOZYME THERAPEUTICS INC DATE OF NAME CHANGE: 20040312 FORMER COMPANY: FORMER CONFORMED NAME: GLOBAL YACHT SERVICES INC DATE OF NAME CHANGE: 20010912 4 1 wk-form4_1780531615.xml FORM 4 X0609 4 2026-06-01 0 0001159036 HALOZYME THERAPEUTICS, INC. HALO 0001528185 Torley Helen false C/O HALOZYME THERAPEUTICS, INC. 12390 EL CAMINO REAL SAN DIEGO CA 92130 1 1 0 0 PRESIDENT AND CEO 1 Common Stock 2026-06-01 4 M 0 20000 12.07 A 787780 D Common Stock 2026-06-01 4 S 0 1610 66.388 D 786170 D Common Stock 2026-06-01 4 S 0 12989 67.41 D 773181 D Common Stock 2026-06-01 4 S 0 5401 68.346 D 767780 D Common Stock 2026-06-02 4 M 0 20000 12.07 A 787780 D Common Stock 2026-06-02 4 S 0 16600 66.314 D 771180 D Common Stock 2026-06-02 4 S 0 3400 66.745 D 767780 D Common Stock 2026-06-03 4 M 0 10000 12.07 A 777780 D Common Stock 2026-06-03 4 S 0 400 66.368 D 777380 D Common Stock 2026-06-03 4 S 0 1500 67.675 D 775880 D Common Stock 2026-06-03 4 S 0 2000 68.736 D 773880 D Common Stock 2026-06-03 4 S 0 6100 69.692 D 767780 D Option to Purchase Common Stock 12.07 2026-06-01 4 M 0 20000 12.07 D 2027-02-22 Common Stock 20000 31923 D Option to Purchase Common Stock 12.07 2026-06-02 4 M 0 20000 12.07 D 2027-02-22 Common Stock 20000 11923 D Option to Purchase Common Stock 12.07 2026-06-03 4 M 0 10000 12.07 D 2027-02-22 Common Stock 10000 1923 D The options exercised and sales reported on this Form 4 were made pursuant to a written trading plan adopted by the Reporting Person on March 21, 2025 in accordance with Rule 10b5-1. The sales of common shares reported on this Form 4 represent shares that were acquired following exercise of stock options with a ten-year term expiring in February 2027. Represents a weighted average sales price per share. The shares were sold at prices ranging from $65.840 to $66.830. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. Represents a weighted average sales price per share. The shares were sold at prices ranging from $66.840 to $67.830. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. Represents a weighted average sales price per share. The shares were sold at prices ranging from $67.840 to $68.820. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. Represents a weighted average sales price per share. The shares were sold at prices ranging from $65.630 to $66.625. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. Represents a weighted average sales price per share. The shares were sold at prices ranging from $66.630 to $67.180. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. Represents a weighted average sales price per share. The shares were sold at prices ranging from $66.000 to $66.770. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. Represents a weighted average sales price per share. The shares were sold at prices ranging from $67.090 to $68.000. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. Represents a weighted average sales price per share. The shares were sold at prices ranging from $68.100 to $69.080. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. Represents a weighted average sales price per share. The shares were sold at prices ranging from $69.120 to $70.050. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. Grant to Reporting Person of options, exercisable over a 4-year period measured from the date of grant, 25% after 12 months, then 1/48th of the Option Shares per month thereafter. The date of grant was February 22, 2017. /s/ James R. Oehler, Attorney-in-Fact 2026-06-03